

SPARC/Sec/SE/2021-22/022

National Stock Exchange of India Ltd, Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051. 4th June 2021

BSE Limited.,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.

Dear Sir/ Madam,

Subject: Corrigendum – 2 to Notice of the Extra-ordinary General Meeting of the Company on Tuesday, 8th June 2021 at 04.00 p.m.

Reference: 1. Our letter dated 17th May 2021 under reference No. SPARC/Sec/SE/2021-22/016 with subject 'Notice of the Extra-ordinary General Meeting of the Company.'

2. Our letter dated 26th May 2021 under reference No. SPARC/Sec/SE/2021-22/018 with subject 'Corrigendum to Notice of the Extra-ordinary General Meeting of the Company on Tuesday, 8th June 2021 at 04.00 p.m.'

With reference to the Notice convening Extra-Ordinary General Meeting of the Company on Tuesday, 8th June 2021 at 04.00 p.m. IST, through Video Conferencing ("VC")/ Other Audio Visual Means ("OAVM"), **('EGM Notice'**) the Company has issued second 'clarificatory' Corrigendum to the shareholders, which is enclosed herewith for your record & dissemination.

Please note that the Corrigendum - 2 is being issued as a measure of abundant precaution with limited intent to clarify on disclosures relating to non-applicability of wilful defaulter related clause and to rectify an inadvertent typographical error pertaining to total pre-issue shareholding of public shareholders mentioned in the EGM Notice

This communication should be read along with the original EGM Notice dated 12th May 2021 as updated by 1st Corrigendum dated May 25, 2021 which was submitted to the Exchange along with the above mentioned letter.

The EGM Notice along with the Corrigendum is also available on the website of the Company and can be accessed using the link: https://www.sparc.life/announcements-disclosures

Inconvenience caused in this regard is deeply regretted.

You are requested to kindly take the same on record.

Yours faithfully,

For Sun Pharma Advanced Research Company Ltd.,

Debashis Dey

Company Secretary

Encls: A/a



SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED

Registered Office: Plot No. 5 & 6/1, Savli G.I.D.C. Estate, Savli - Vadodara Highway, Manjusar, Vadodara - 391775, Gujarat, India.

CIN: L73100GJ2006PLC047837 Website: www.sparc.life

CORRIGENDUM TO EGM NOTICE

The Notice of Extra-ordinary General Meeting dated May 12, 2021 ("EGM Notice"), Corrigendum dated May 25, 2021 (Corrigendum – 1") shall be read with this corrigendum ("Corrigendum - 2").

This Corrigendum - 2 is issued as a measure of abundant precaution, with limited intent to clarify on disclosures relating to non-applicability of wilful defaulter related clause and to rectify an inadvertent typographical error pertaining to total pre-issue shareholding of public shareholders mentioned in the EGM Notice.

- 1. In the table under point 4 of the Explanatory Statement to the EGM Notice, the Pre-Issue no. of equity shares against category 'Total Public shareholding (B)' should be read as '826,40,276' instead of '826,40,246'.
- 2. In the Notes under the table under point 6 of the Explanatory Statement to the EGM Notice (as amended by Corrigendum -1), Note ⁵ shall be updated and read as follows:
 - ⁵ Name of Senior managing Official(s)/Designated Partner(s) (since Allotee is a FPI Category 2/AIF registered with SEBI, with no single natural person's stake being more than the threshold limit or 25% of the total ownership or voting rights of the respective FPI/AIF).
- 3. After point no. 16 of the Explanatory Statement of the EGM Notice, following paragraph shall be added:

17. Wilful Defaulter:

Neither the Company, nor any of the promoters or directors of the Company have been declared as wilful defaulter, hence disclosures specified in Schedule VI of ICDR Regulations is not applicable.

By order of the Board of Directors For Sun Pharma Advanced Research Company Limited

Debashis Dey Company Secretary

Place: Mumbai Date: June 04, 2021